Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 267

1.

Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.

Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, Tinsley S, Dickson G, Burnett AK, Hills RK, Linch DC.

J Clin Oncol. 2015 Jun 20;33(18):2072-83. doi: 10.1200/JCO.2014.59.2022. Epub 2015 May 11.

PMID:
25964253
2.

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.

Lazenby M, Hills R, Burnett AK, Zabkiewicz J.

Leuk Res. 2015 Jun;39(6):617-24. doi: 10.1016/j.leukres.2015.03.016. Epub 2015 Mar 30.

3.

An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34(+)  CD38(low) blasts.

Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK, Hills RK.

Br J Haematol. 2015 Jul;170(1):80-4. doi: 10.1111/bjh.13398. Epub 2015 Apr 14.

PMID:
25876768
4.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group.

Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1.

PMID:
25833957
5.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

6.

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK.

Blood. 2015 May 7;125(19):2923-32. doi: 10.1182/blood-2014-10-608117. Epub 2015 Mar 24.

PMID:
25805811
7.

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse.

Coles SJ, Gilmour MN, Reid R, Knapper S, Burnett AK, Man S, Tonks A, Darley RL.

Leukemia. 2015 Mar 9. doi: 10.1038/leu.2015.62. [Epub ahead of print] No abstract available.

PMID:
25748687
8.

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.

Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D.

Leukemia. 2015 Jun;29(6):1312-9. doi: 10.1038/leu.2015.38. Epub 2015 Feb 13.

PMID:
25676423
9.

A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia.

Russell NH, Kjeldsen L, Craddock C, Pagliuca A, Yin JA, Clark RE, Howman A, Hills RK, Burnett AK.

Leukemia. 2015 Jul;29(7):1478-84. doi: 10.1038/leu.2014.319. Epub 2014 Nov 7.

PMID:
25376374
10.

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH.

Leukemia. 2015 Feb;29(2):312-20. doi: 10.1038/leu.2014.242. Epub 2014 Aug 12.

PMID:
25113226
11.

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK.

Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. Review.

12.

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE.

Blood. 2014 Jul 10;124(2):273-6. doi: 10.1182/blood-2014-02-554667. Epub 2014 May 22.

13.

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.

Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK.

Leukemia. 2014 Oct;28(10):1953-9. doi: 10.1038/leu.2014.90. Epub 2014 Feb 27.

PMID:
24573385
14.

Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials.

Mohamed I, Hills RK, Burnett AK.

Br J Haematol. 2014 Apr;165(1):147-51. doi: 10.1111/bjh.12705. Epub 2013 Dec 23. No abstract available.

PMID:
24372387
15.

The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.

Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK, Darley RL.

Haematologica. 2014 May;99(5):858-64. doi: 10.3324/haematol.2013.096487. Epub 2013 Dec 13.

16.

Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1.

Seedhouse CH, Mills KI, Ahluwalia S, Grundy M, Shang S, Burnett AK, Russell NH, Pallis M.

Leuk Res. 2014 Jan;38(1):131-7. doi: 10.1016/j.leukres.2013.10.030. Epub 2013 Nov 8.

PMID:
24268349
17.

Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling.

Hole PS, Zabkiewicz J, Munje C, Newton Z, Pearn L, White P, Marquez N, Hills RK, Burnett AK, Tonks A, Darley RL.

Blood. 2013 Nov 7;122(19):3322-30. doi: 10.1182/blood-2013-04-491944. Epub 2013 Oct 2.

18.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, Burnett AK.

J Clin Oncol. 2013 Nov 10;31(32):4123-31. doi: 10.1200/JCO.2013.49.1753. Epub 2013 Sep 23.

19.

ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.

El-Sharkawi D, Ali A, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE.

Leuk Lymphoma. 2014 Jun;55(6):1326-31. doi: 10.3109/10428194.2013.833332. Epub 2013 Oct 9.

PMID:
23952244
20.

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D.

J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk